Crooks P A, Li M, Dwoskin L P
College of Pharmacy, University of Kentucky, Lexington 40536-0082, USA.
Drug Metab Dispos. 1997 Jan;25(1):47-54.
The time course of nicotine metabolite appearance in brain from 5 min-18 hr after subcutaneous administration of S-(-)-[3H-N-methyl]nicotine was determined. Results demonstrated that metabolite appearance in brain was greatest at 4 hr postadministration, whereas levels of nicotine were greatly diminished at this time point. For determination of N-demethylated metabolites, (+/-)-[2'-14C]nicotine was administered subcutaneously to rats, and the presence of nicotine and nicotine metabolites in brain supernatant was determined 4 hr postadministration. Using high-performance liquid radiochromatographic analysis, nicotine and three nicotine metabolites (cotinine, nornicotine, and norcotinine) were identified in brain, together with a fourth minor, unidentified metabolite. After subcutaneous administration of S-(-)-[G-3H]cotinine, significant amounts of cotinine were found in brain over an 18-hr postadministration period; however, no cotinine metabolites were detected. Therefore, cotinine is able to pass the blood-brain barrier and access the central nervous system, but is not biotransformed in brain. Thus, this is the first report of norcotinine as a central nervous system nicotine metabolite. Data indicate that norcotinine detected in brain after peripheral nicotine administration most likely originates from 5'-C-oxidation of brain nornicotine, rather than from N-demethylation of cotinine, as occurs peripherally. Because peripheral biotransformation of nicotine to nornicotine is a minor pathway, the relatively high levels of nornicotine found in brain after peripheral nicotine administration suggest that nornicotine is formed via oxidative N-demethylation of nicotine locally in brain. Nornicotine is pharmacologically active; thus, its presence in brain after peripheral nicotine administration indicates that nornicotine may contribute to the neuropharmacological effects of nicotine and tobacco use.
测定了皮下注射S-(-)-[3H-N-甲基]尼古丁后5分钟至18小时内尼古丁代谢产物在脑中出现的时间进程。结果表明,给药后4小时脑中代谢产物的出现量最大,而此时尼古丁水平大幅下降。为了测定N-去甲基化代谢产物,给大鼠皮下注射(±)-[2'-14C]尼古丁,并在给药后4小时测定脑上清液中尼古丁和尼古丁代谢产物的存在情况。使用高效液相放射性色谱分析,在脑中鉴定出尼古丁和三种尼古丁代谢产物(可替宁、去甲烟碱和去甲可替宁),以及第四种少量未鉴定的代谢产物。皮下注射S-(-)-[G-3H]可替宁后,在给药后18小时内脑中发现了大量可替宁;然而,未检测到可替宁代谢产物。因此,可替宁能够穿过血脑屏障进入中枢神经系统,但在脑中不会发生生物转化。因此,这是关于去甲可替宁作为中枢神经系统尼古丁代谢产物的首次报道。数据表明,外周给予尼古丁后在脑中检测到的去甲可替宁很可能源自脑内去甲烟碱的5'-C-氧化,而非外周发生的可替宁N-去甲基化。由于尼古丁外周生物转化为去甲烟碱是一条次要途径,外周给予尼古丁后脑中发现的相对高水平的去甲烟碱表明去甲烟碱是通过脑内尼古丁的氧化N-去甲基化在局部形成的。去甲烟碱具有药理活性;因此,外周给予尼古丁后其在脑中的存在表明去甲烟碱可能有助于尼古丁和烟草使用的神经药理学效应。